Kymera Therapeutics Inc

Kymera Therapeutics delivered a sharply disappointing fourth quarter, posting a loss of $0.97 per share against a consensus estimate of $0.79, a miss of 22.78%, while revenue collapsed 61.2% year-over-year to just $2.87 million, falling well short of the $17.30 million analysts had anticipated. The primary culprit was a steep decline in collaboration revenue as the company's revenue mix shifted away from its Sanofi partnership toward the newer Gilead Sciences arrangement, compounding the shortfall as R&D expenses climbed to $83.83 million in the quarter from $71.82 million a year earlier, reflecting accelerating investment in its STAT6 degrader program KT-621. The losses, however, are being framed by management as the cost of building a high-conviction clinical pipeline, and a $692 million equity offering completed in December leaves Kymera with roughly $1.62 billion in cash, extending its runway into 2029. Key catalysts ahead include Phase 2b data from the KT-621 atopic dermatitis trial by mid-2027, asthma data in late 2027, and first-in-human Phase 1 results for IRF5 degrader KT-579 in the second half of 2026, milestones that analysts broadly view as the true test of the company's valuation thesis.